<DOC>
	<DOCNO>NCT01161316</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety combination mFOLFOX-6 plus cetuximab 8 cycle follow mFOLFOX-6 plus cetuximab single agent ( s/a ) cetuximab maintenance therapy patient ( pt ) metastatic colorectal cancer ( mCRC ) .</brief_summary>
	<brief_title>Safety Efficacy Study mFOLFOX-6 Plus Cetuximab 8 Cycles Followed mFOLFOX-6 Plus Cetuximab Single Agent Cetuximab Maintenance Therapy Patients With Metastatic Colorectal Cancer WT KRAS Tumours</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Written inform consent . Patients age ≥ 18 year &lt; 71 Patients ECOG performance status ≤ 2 Confirmed histological diagnosis colorectal carcinoma metastatic disease wildtype KRAS . Presence least one target lesion measurable onedimensionally ( locate irradiate region ) . Life expectancy great 12 week . First evidence chemotherapynaïve metastatic disease . Adjuvant chemotherapy allow 6 month since treatment finish sign disease progression , neither treatment 6 month follow completion . Adequate medullar reserve : Absolute neutrophil count ≥ 1.5 x 109/L Platelet count ≥ 100 x 109/L Haemoglobin ≥ 9 g/dL Adequate renal function : Creatinine clearance &gt; 30 mL/min , calculate use CockroffGault formula , serum creatinine &lt; 2 mg/dL 177 umol/L An adequate liver function : ASAT ( SGOT ) ALAT ( SGPT ) ≤ 2.5 x ULN ( ≤ 5 x ULN liver metastasis ) . Total bilirubin &lt; 1.5 x ULN . Alkaline phosphatase ≤ 2.5 x ULN ( ≤ 5 x ULN case liver metastases ≤ 10 x ULN case bone metastasis ) To receive prior systemic treatment metastatic disease Diagnosis suspicion brain leptomeningeal metastasis Major surgery radiotherapy ( except antalgic surgery include measurable target lesion ) 4 week prior inclusion study . Previous administration monoclonal antibody , agent inhibit EGFR signal transduction EGFRtargeted treatment . Participation another clinical trial drug within previous 30 day . Neoplasm 2 year prior enter study , except nonmelanoma skin carcinoma situ cervix carcinoma . Evidence previous acute hypersensitivity reaction degree treatment 's component . Clinically relevant peripheral neuropathy . Signs symptom , moment enter study , acute subacute bowel obstruction . A history acute episode ischemic heart disease ( angina acute myocardial infarction ) within previous 12 month elevate risk heart failure decompensation uncontrolled arrhythmia . Serious active infection , include active tuberculosis HIV diagnosis . Chronic immunological hormonal treatment , except hormone replacement treatment physiological dos . Known drug alcohol abuse . Legal incapacity limit legal capacity . Pregnancy breastfeed . Premenopausal woman must negative pregnancy test urine blood enter trial . Patients partner must take contraceptive measure ( hormonal , barrier , abstinence ) possibility conception exist , study 3 month end treatment thereof . Any geographical social circumstance medical psychological alteration , investigator 's opinion , allow patient conclude study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>metastatic colorectal cancer</keyword>
	<keyword>wild-type KRAS tumour</keyword>
	<keyword>cetuximab</keyword>
	<keyword>mFOLFOX-6</keyword>
</DOC>